发明名称 TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE
摘要 The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. The compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.
申请公布号 WO9734589(A1) 申请公布日期 1997.09.25
申请号 WO1997US04551 申请日期 1997.03.19
申请人 PRESIDENT AND FELLOWS OF HARVARD COLLEGE;CHILDREN'S MEDICAL CENTER CORPORATION;ION PHARMACEUTICALS, INC. 发明人 BRUGNARA, CARLO;HALPERIN, JOSE;BELLOT, EMILE, M., JR.;FROIMOWITZ, MARK;LOMBARDY, RICHARD, J.;CLIFFORD, JOHN, J.;GAO, YING-DUO;HAIDAR, REEM, M.;KELLEHER, EUGENE, W.;KHER, FALGUNI, M.;MOUSSA, ADEL, M.;SACHDEVA, YESH, P.;SUN, MINGHUA;TAFT, HEATHER, N.
分类号 C07D295/14;A61K31/015;A61K31/02;A61K31/03;A61K31/045;A61K31/05;A61K31/075;A61K31/085;A61K31/10;A61K31/11;A61K31/135;A61K31/14;A61K31/15;A61K31/165;A61K31/19;A61K31/195;A61K31/215;A61K31/275;A61K31/34;A61K31/381;A61K31/40;A61K31/44;A61K31/4453;A61P35/00;A61P43/00;C07C15/16;C07C17/35;C07C22/04;C07C25/18;C07C33/24;C07C33/28;C07C33/34;C07C33/46;C07C39/15;C07C39/367;C07C43/164;C07C43/225;C07C43/23;C07C45/00;C07C45/44;C07C47/23;C07C47/24;C07C47/273;C07C49/163;C07C49/215;C07C49/233;C07C57/38;C07C57/40;C07C57/46;C07C57/58;C07C69/616;C07C69/65;C07C69/76;C07C211/27;C07C211/52;C07C211/54;C07C215/68;C07C217/18;C07C217/20;C07C229/14;C07C233/11;C07C239/20;C07C239/22;C07C255/33;C07C255/35;C07C259/06;C07C321/10;C07D207/08;C07D207/26;C07D213/06;C07D213/16;C07D213/20;C07D213/30;C07D295/145;C07D307/33;C07F7/08;C07F7/10;C07F7/18;C07F7/30;C07F9/535;(IPC1-7):A61K31/14 主分类号 C07D295/14
代理机构 代理人
主权项
地址